Publications by authors named "H R Brunner"
Objective: Prognostic factors associated with medication discontinuation in children with juvenile dermatomyositis (JDM) remain largely elusive. We aim to identify the predictors of medication-free remission (MFR) in children with JDM.
Methods: In this retrospective study, patients diagnosed with JDM according to Peter & Bohan criteria and followed for ≥18 months at a tertiary care center from 2006 through 2022 were included.
Purpose: is one of the most frequently mutated genes in intellectual disability cohorts. Thus, far few adult-aged patients with -related disorder have been described, which limits our understanding of the disease's natural history and our ability to counsel patients and their families.
Methods: Data on patients aged 18+ years with -related disorder were collected through an online questionnaire completed by clinicians and parents.
Article Synopsis
- Over 300,000 children in the U.S. have pediatric rheumatic diseases (PRDs), with juvenile idiopathic arthritis (JIA), childhood-onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM) being the most prevalent.
- The first biologic therapy for JIA, Etanercept, was approved in 1999, followed by other similar treatments that have significantly improved disease outcomes, though options for cSLE and JDM remain limited.
- The review explores the challenges in treating various PRDs, highlights advancements in treatment, and discusses current regulatory conditions affecting bDMARD and tsDMARD approvals.
Article Synopsis
- The syndrome of undifferentiated recurrent fevers (SURF) is marked by recurring fevers and inflammation without a clear hereditary cause, differing from PFAPA syndrome.
- A study involving 46 patients highlighted that those with SURF often exhibited more skin rashes and joint pain, while having fewer cases of throat infections and swollen lymph nodes compared to PFAPA patients.
- The results also indicated that patients with SURF showed higher levels of pro-inflammatory cytokines and frequently needed biologic treatments, suggesting distinct clinical features and potential genetic factors that warrant further investigation.
Background: Uveitis is an inflammatory ocular disease secondary to disruption of the retinal pigmented epithelium (RPE) and blood retinal barrier (BRB). Known clinical factors do not accurately predict uveitis risk in Juvenile Idiopathic Arthritis (JIA). Tear fluid is easily obtained for biomarker study.
View Article and Find Full Text PDF